Women face high risk of developing breast cancer following radiotherapy for Hodgkin’s DiseaseMarch 21, 2002Women who have received radiotherapy for Hodgkin’s Disease have a three times higher relative risk of developing breast cancer than women from the general population, Professor Dietlind Wahner-Roedler told the 3rd European Breast Cancer Conference today (Saturday 23 March). If the women were younger than 30 when they received the treatment their relative risk was even higher at eight times the normal risk. If the spleen had been removed from these younger women as part of the treatment (splenectomy), then they faced a ten times higher relative risk than the general population, while a family history of breast cancer increased their chances of developing the disease 11-fold above the general population. This risk is so high that the professor said these women might want to consider prophylactic double mastectomy. However, Prof Wahner-Roedler, assistant professor and consultant in Internal Medicine and Breast Clinic at the Mayo Clinic, Rochester, USA, said that radiotherapy techniques have improved in recent years and she would expect the risk to have decreased with modern treatments. Prof Wahner-Roedler and her colleagues reviewed the records of 2,202 women with Hodgkin’s Disease who were seen at Mayo Clinic between 1950 and 1993 and studied the records of 653 women, who were treated at the Mayo Clinic with supradiaphragmatic radiation therapy (SDRT)1. Four patients who were diagnosed with breast cancer prior to the diagnosis of Hodgkin’s Disease were excluded from the analysis. They found that 30 women had developed breast cancer, of whom four had developed cancer at different times in both breasts. They found that the relative risk, expressed as SMR (standard morbidity ratio)2, of developing breast cancer increased significantly after 15 years of follow-up and that this increase continued through 30 years of follow-up. Women aged 30 and over at the time of SDRT had only a slightly higher than normal relative risk of developing breast cancer. The relative risk of breast cancer in this age group was significantly higher in women with a positive family history of breast cancer compared to those with a negative family history; similarly the women in this age group who had undergone a splenectomy had a significantly increased relative risk compared to those who had not undergone a splenectomy. In contrast, in women who received SDRT under the age of 30, the risk in those with a family history was not significantly higher than in those without a family history; similarly the risk in this age group was not significantly higher in those with a splenectomy compared to those without a splenectomy. SDRT posed the greatest danger of causing subsequent breast cancer to women under 30 at the time of treatment. Prof Wahner-Roedler said: “The impact of radiation therapy on younger women is so severe that it makes the impact of having a family history of breast cancer not significant.” Half of the tumours were found by the women themselves during self-examination, 13 were found by mammographic screening and four by clinical examination. Prof Wahner-Roedler said: “It is important to realise that breast cancer diagnosed now reflects treatment methods for Hodgkin’s Disease from more than ten years ago. During the past several years, splenectomy has been abandoned by many centres. Modern combined modality therapy with improved techniques, reduced fields and reduced doses of radiation is expected to lower the increased risk of breast cancer. Further studies will be required to assess the effect of current treatment methods for Hodgkin’s Disease.” She recommended vigilance for women who have been treated for Hodgkin’s Disease. “We recommend that they should have professional breast examinations every six months. For patients treated under the age of 20, we recommend annual mammography starting ten years after SDRT, but not before the age of 25 as the majority of breast cancers have been reported after the age of 25. For patients treated at age 20 or older, we recommend routine screening to start 10 years after SDRT or at age 35, which ever comes first. Bilateral prophylactic mastectomy should be discussed with patients who have a strong family history.” | |||||||||||||||||||||
|
Related Breast Cancer Current Events and Breast Cancer News Articles Clue to genetic cause of fatal birth defect A novel enzyme may play a major role in anencephaly, offering hope for a genetic test or even therapy for the rare fatal birth defect in which the brain fails to develop, according to a study from researchers at the University of Illinois at Chicago College of Medicine. Bisphenol A linked to chemotherapy resistance Exposure to bisphenol A (BPA) may reduce the effectiveness of chemotherapy treatments, say University of Cincinnati (UC) scientists. Tamoxifen chemoprevention tied to early detection of breast cancer The drug tamoxifen does not prevent or treat estrogen receptor (ER) negative breast cancer, but it can make the disease easier to find, researchers report in the Oct. 1 Journal of the National Cancer Institute. Herbal Menopause Therapy a Good Fit for Breast Cancer Patients? When it comes to understanding the effectiveness and safety of using herbal therapies with other drugs, much is unknown. Now, a University of Missouri researcher will study how black cohosh - an herbal supplement often used to relieve hot flashes in menopausal women - interacts with tamoxifen, a common drug used to treat breast cancer. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics Novel platform technologies and key advances in genomics are rapidly driving the development of molecular diagnostics, reports Genetic Engineering and Biotechnology News (GEN). Study looks at psychological impact of gene test for breast cancer Personal beliefs about inconclusive DNA testing for hereditary breast cancer are associated with cancer-related worry, and such beliefs are an especially strong predictor of whether women had been able to leave the period of DNA-testing behind. Second lumpectomy for breast cancer reduces survival rates A majority of women with breast cancer today are candidates for lumpectomy, allowing for conservation of most of their breast tissue. MRI spots DCIS in mice A new magnetic resonance imaging procedure can detect very early breast cancer in mice, including ductal carcinoma in situ (DCIS), a precursor to invasive cancer. Some of the tumors detected were less than 300 microns in diameter, the smallest cancers ever detected by MRI. Birth size is a marker of susceptibility to breast cancer later in life Birth size, and in particular birth length, correlates with subsequent risk of breast cancer in adulthood, according to a new study published in PLoS Medicine by researchers at the London School of Hygiene and Tropical Medicine. Social class dictates cancer risk Cervical and lung cancer are more common in poor people while rates of breast cancer and melanoma are higher in the wealthy. More Breast Cancer Current Events and Breast Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||